title: Continuous treatment of plaque-type psoriasis with etanercept: an observational long-term experience.
abstract: To assess the long-term efficacy and safety profile and the patient-reported outcomes (PRO) in patients with moderate-to-severe plaque-type psoriasis receiving continuous etanercept treatment. An open-label study was conducted to evaluate etanercept as long-term treatment for moderate-to-severe plaque psoriasis. Continuous therapy was administered at a dose of 50 mg subcutaneously twice weekly for 12 weeks followed by a continuous treatment with 50 mg subcutaneously once weekly or 25 mg twice weekly throughout a 96-week study. The primary measure of efficacy was the proportion of patients with PASI 75 at week 24, 48 and 96. Patient-reported outcomes (PRO) were also assessed during the study, at week 24, 48 and 96, including the Dermatology Life Quality Index (DLQI) and the Psoriasis Disability Index (PDI). At baseline, mean PASI score, DLQI and PDI for patients eligible to initiate treatment with etanercept showed significant disease severity, quality-of-life impairment and psoriasis-related disability. At week 96, patients showed statistically significant and meaningful improvements. The continuous etanercept regimen provided a consistent improvement in both clinical disease parameters and PRO measures.
authors.affiliation: Department of Dermatology, University of Rome Tor Vergata, Italy. espositomaria@virgilio.it
authors.forename: M
authors.initials: M
authors.lastname: Esposito
authors.forename: A
authors.initials: A
authors.lastname: Giunta
authors.forename: A
authors.initials: A
authors.lastname: Mazzotta
authors.forename: G
authors.initials: G
authors.lastname: Babino
authors.forename: M
authors.initials: M
authors.lastname: Talamonti
authors.forename: M S
authors.initials: MS
authors.lastname: Chimenti
authors.forename: S
authors.initials: S
authors.lastname: Chimenti
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000068800:Etanercept; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011565:Psoriasis / Q000188:drug therapy*; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use*; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000068800:Etanercept